Model to predict on-treatment restoration of functional HBV-specific CD8


Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
06 2022
Historique:
revised: 12 10 2022
received: 12 09 2021
accepted: 14 02 2022
pubmed: 1 3 2022
medline: 27 5 2022
entrez: 28 2 2022
Statut: ppublish

Résumé

Hepatitis B virus (HBV)-specific CD8 To predict this response with variables involved in T-cell exhaustion for use as a treatment stopping tool. In NUC-treated CHBe(-) patients, we considered a functional response in cases with HBV-specific CD8 We developed an LRM that predicted the presence of a proliferative type I cytokine-secreting CD8 Short-term low-level antigen exposure and early long-term NUC treatment influence the restoration of a functional HBV-specific CD8

Sections du résumé

BACKGROUND
Hepatitis B virus (HBV)-specific CD8
AIM
To predict this response with variables involved in T-cell exhaustion for use as a treatment stopping tool.
METHODS
In NUC-treated CHBe(-) patients, we considered a functional response in cases with HBV-specific CD8
RESULTS
We developed an LRM that predicted the presence of a proliferative type I cytokine-secreting CD8
CONCLUSIONS
Short-term low-level antigen exposure and early long-term NUC treatment influence the restoration of a functional HBV-specific CD8

Identifiants

pubmed: 35224746
doi: 10.1111/apt.16850
pmc: PMC9305412
doi:

Substances chimiques

Antiviral Agents 0
Cytokines 0
DNA, Viral 0
Epitopes 0
Hepatitis B Surface Antigens 0
Hepatitis B e Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1545-1559

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Références

Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195619
J Hepatol. 2018 Sep;69(3):584-593
pubmed: 29758333
Gut. 2019 May;68(5):905-915
pubmed: 30622109
Antiviral Res. 2021 Jan;185:104992
pubmed: 33279523
Viruses. 2021 Feb 26;13(3):
pubmed: 33652619
J Hepatol. 2017 Feb;66(2):275-281
pubmed: 27639844
Gastroenterology. 2012 Sep;143(3):629-636.e1
pubmed: 22659218
J Clin Microbiol. 2017 Oct;55(10):2972-2982
pubmed: 28747369
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Virol. 2004 Jun;78(11):5707-19
pubmed: 15140968
Aliment Pharmacol Ther. 2011 Dec;34(11-12):1337-46
pubmed: 22007836
Int J Infect Dis. 2019 Sep;86:201-207
pubmed: 31394205
Hepatology. 2016 May;63(5):1481-92
pubmed: 27100145
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
J Clin Invest. 1998 Sep 1;102(5):968-75
pubmed: 9727065
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Nat Rev Drug Discov. 2019 Nov;18(11):827-844
pubmed: 31455905
Antivir Ther. 2019;24(2):105-115
pubmed: 30511941
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
J Immunol Methods. 1995 Apr 12;181(1):45-54
pubmed: 7537312
Gastroenterology. 1999 Dec;117(6):1386-96
pubmed: 10579980
J Hepatol. 2019 Apr;70(4):615-625
pubmed: 30529504
Nat Rev Immunol. 2022 Jan;22(1):19-32
pubmed: 34002067
J Hepatol. 2011 Jul;55(1):183-91
pubmed: 21238520
J Virol. 2003 Apr;77(8):4911-27
pubmed: 12663797
Gastroenterology. 2020 Aug;159(2):652-664
pubmed: 32302614
Hepatology. 2017 Oct;66(4):1296-1313
pubmed: 28762522
Curr Infect Dis Rep. 2018 Mar 14;20(4):4
pubmed: 29542023
J Clin Invest. 2018 Feb 1;128(2):668-681
pubmed: 29309050
Gastroenterology. 2012 Oct;143(4):963-73.e9
pubmed: 22796241
Antimicrob Agents Chemother. 2008 Jan;52(1):312-20
pubmed: 17984230
J Hepatol. 2021 May;74(5):1064-1074
pubmed: 33278456
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):662-675
pubmed: 31548710
Hepatology. 2021 Feb;73(2):843-852
pubmed: 32810321
Antivir Ther. 2010;15 Suppl 3:25-33
pubmed: 21041901
J Hepatol. 2017 Nov;67(5):918-924
pubmed: 28736139
Aliment Pharmacol Ther. 2022 Jun;55(12):1545-1559
pubmed: 35224746
Gastroenterology. 2016 Jan;150(1):194-205
pubmed: 26416327

Auteurs

Julia Peña-Asensio (J)

Department of Biology of Systems, University of Alcalá, Alcalá de Henares, Spain.

Henar Calvo (H)

Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.

Joaquín Miquel (J)

Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.

Eduardo Sanz-de-Villalobos (E)

Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.

Alejandro González-Praetorius (A)

Section of Microbiology, Guadalajara University Hospital, Guadalajara, Spain.

Miguel Torralba (M)

Service of Internal Medicine, Guadalajara University Hospital, Guadalajara, Spain.
Department of Medicine & Medical Specialties, University of Alcalá, Alcalá de Henares, Spain.

Juan-Ramón Larrubia (JR)

Section of Gastroenterology, Guadalajara University Hospital, Guadalajara, Spain.
Department of Medicine & Medical Specialties, University of Alcalá, Alcalá de Henares, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH